<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/727DAA84-5778-46E5-AD06-516799EFA403"><gtr:id>727DAA84-5778-46E5-AD06-516799EFA403</gtr:id><gtr:name>Almac Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B85C9507-1FE0-420C-BAC8-8DC91772F172"><gtr:id>B85C9507-1FE0-420C-BAC8-8DC91772F172</gtr:id><gtr:name>Kantonsspital St. Gallen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ED28E77E-59C1-4572-8D58-6FDC7D27006E"><gtr:id>ED28E77E-59C1-4572-8D58-6FDC7D27006E</gtr:id><gtr:name>Clovis Oncology, inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3"><gtr:id>F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3</gtr:id><gtr:name>Swiss Group for Cancer Clinical Research (SAKK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/727DAA84-5778-46E5-AD06-516799EFA403"><gtr:id>727DAA84-5778-46E5-AD06-516799EFA403</gtr:id><gtr:name>Almac Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B85C9507-1FE0-420C-BAC8-8DC91772F172"><gtr:id>B85C9507-1FE0-420C-BAC8-8DC91772F172</gtr:id><gtr:name>Kantonsspital St. Gallen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ED28E77E-59C1-4572-8D58-6FDC7D27006E"><gtr:id>ED28E77E-59C1-4572-8D58-6FDC7D27006E</gtr:id><gtr:name>Clovis Oncology, inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3"><gtr:id>F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3</gtr:id><gtr:name>Swiss Group for Cancer Clinical Research (SAKK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1FFD79A0-0681-4141-A504-FDE130EF7F33"><gtr:id>1FFD79A0-0681-4141-A504-FDE130EF7F33</gtr:id><gtr:firstName>Mahesh</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F6"><gtr:id>42D53A6C-0B10-42A1-8F49-466FC79484EE</gtr:id><gtr:title>Improving Outcomes for Men with Prostate Cancer.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/6</gtr:grantReference><gtr:abstractText>We seek to improve outcomes, reduce side-effects and reduce over-diagnosis and over-treatment in the most common male cancer: prostate cancer.|Prostate cancer is a big problem. It is increasingly common (30,000 new UK cases in 2005), particularly earlier stages of disease. We need to improve outcomes.|In recent years, we have shown that bisphosphonate drugs may make men with metastases live longer, that men live longer if given radiotherapy with hormone therapy (the mainstay of treatment for more advanced disease) and that, in men with less advanced disease, higher doses of radiotherapy can give better prostate cancer outcomes without increasing unwanted effects when using modern radiotherapy equipment.|We have 3 studies open to recruitment and one to open. STAMPEDE, for men starting hormone therapy, uses new research methods to assess three quite different drugs (chemotherapy, bone-protecting drug, cox-2 inhibitor) alone or in pairs, each with standard hormone therapy. PATCH is looking at a different way of giving hormone therapy to reduce toxicity and improve outcomes. RADICALS studies when and how best to use radiotherapy and hormone therapy after surgery (radical prostatectomy) for prostate cancer, balancing cancer outcomes with potential unwanted effects. The new study uses magnetic resonance imaging to diagnose cancers that require treatment from those that do not.</gtr:abstractText><gtr:technicalSummary>We wish to reduce over-diagnosis of clinically irrelevant tumours and reduce over-treatment. We wish to design and implement methods for speeding up trials and prostate cancer is a good testing ground for this.|In recent years, we have shown that:|a first-generation bisphosphonate drug may make men with metastases live longer (PR05, ISRCTN38477744) but not men with earlier disease (PR04, ISRCTN61384873)|men live longer if given radiotherapy with hormone therapy, the mainstay of treatment for more advanced disease (PR07, NCIC PR.3, ISRCTN24991896)|in men with less advanced disease, higher doses of radiotherapy can give better prostate cancer outcomes without increasing unwanted effects when using modern conformal radiotherapy methods (RT01, ISRCTN47772397). in men with less advanced disease, higher doses of radiotherapy can give better prostate cancer outcomes without increasing unwanted effects when using modern conformal radiotherapy methods (RT01, ISRCTN47772397).|We have 3 studies open to recruitment and one to open. STAMPEDE (MRC PR08, ISRCTN78818544) is a flagship trial for men starting long-term hormone therapy. It uses new multi-arm multi-stage (MAMS) methods to supplement standard hormone therapy with 5 combinations of 3 drugs: doctaxel (a taxane chemotherapy), zoledronic acid (a potent, third-generation bisphosphonate) and celecoxib (a selective cox-2 inhibitor). More than 1500 patients from the UK and Switzerland have already joined this 6-arm trial.|PATCH (PR09, ISRCTN70406718) looks at whether oestrogen-based therapy can be administered more safely using patches rather than tablets; this method bypasses the liver pathways and cardiovascular problems should be reduced and efficacy improved. This is a novel idea. PATCH reached its target of 250 patients and will continue further.|RADICALS (PR10, NCIC PR-13, ISRCTN40814031) assesses two important questions for men who have chosen radical prostatectomy for localised prostate cancer: (i) the use and timing of post-operative radiotherapy, balancing potential efficacy and potential over-treatment; and (ii) the use of hormone therapy with any post-operative radiotherapy. RADICALS will recruit around 4,000 men from the UK, Canada, Denmark and beyond.|The new study evaluates multi-functional MRI in the diagnosis and characterisation of prostate cancer with a view to reducing over-diagnosis of clinically irrelevant tumours and over-treatment.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1393000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE biobank</gtr:description><gtr:id>9C7ECF56-882B-4A62-B54A-D66A5FA0535F</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d850b3b41d70.44308347-2</gtr:outcomeId><gtr:partnerContribution>Will host samples.</gtr:partnerContribution><gtr:piContribution>Competitive process to choose sites to host a new Biobank for the STAMPEDE trial. Manchester and Cardiff were the winners. Grant funding has been submitted for.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>STAMPEDE &amp;quot;metformin comparison&amp;quot; - Trial Development Group</gtr:description><gtr:id>A74A5C1F-7991-406C-B214-B4863DEE2C7C</gtr:id><gtr:impact>Clinical trial opens in May-2016. Results due in 10 years</gtr:impact><gtr:outcomeId>56d84c914c5d56.49074150-3</gtr:outcomeId><gtr:partnerContribution>Manchester, Warwick, St Gallen - clinical
London - statistical, operational, trials</gtr:partnerContribution><gtr:piContribution>Core group developing the &amp;quot;metformin comparison&amp;quot; in STAMPEDE which led to a clinical trial in prostate cancer with funding support from CRUK</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astellas Pharma</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>46129D33-DB97-4E03-9DAD-76B4A6BEF496</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-9</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Prostate Cancer CSG</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>BF724E0C-29C2-4BE0-A42E-C5FB0DDC4FB7</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-7</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE &amp;quot;metformin comparison&amp;quot; - Trial Development Group</gtr:description><gtr:id>11DF7609-4A2F-46DD-AC8B-A827A990C77F</gtr:id><gtr:impact>Clinical trial opens in May-2016. Results due in 10 years</gtr:impact><gtr:outcomeId>56d84c914c5d56.49074150-4</gtr:outcomeId><gtr:partnerContribution>Manchester, Warwick, St Gallen - clinical
London - statistical, operational, trials</gtr:partnerContribution><gtr:piContribution>Core group developing the &amp;quot;metformin comparison&amp;quot; in STAMPEDE which led to a clinical trial in prostate cancer with funding support from CRUK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE &amp;quot;metformin comparison&amp;quot; - Trial Development Group</gtr:description><gtr:id>3E2ED078-2DF1-4E6B-9642-B46B5F90BDB9</gtr:id><gtr:impact>Clinical trial opens in May-2016. Results due in 10 years</gtr:impact><gtr:outcomeId>56d84c914c5d56.49074150-2</gtr:outcomeId><gtr:partnerContribution>Manchester, Warwick, St Gallen - clinical
London - statistical, operational, trials</gtr:partnerContribution><gtr:piContribution>Core group developing the &amp;quot;metformin comparison&amp;quot; in STAMPEDE which led to a clinical trial in prostate cancer with funding support from CRUK</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>A5DEC9F8-E798-4ACF-8D33-BC9BE1E3A6B4</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-6</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STRATOSPHERE Consortium (previousy S-STAMPEDE working group)</gtr:description><gtr:id>3D79BFEB-398F-447C-B1D4-25C0A74AF5DF</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d84f24de4eb1.76889181-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input into design
+ Sample processing by Almac</gtr:partnerContribution><gtr:piContribution>Developing a stratified medicine trial in prostate cancer - work ongoing but agreement that Almac will pay to process samples</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>C0814843-1214-46E3-835A-BE31C85209A5</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-2</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>1DA878C6-8D2D-43CC-BF7F-7BC837E4AF19</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-3</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kantonsspital St. Gallen</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>STAMPEDE &amp;quot;metformin comparison&amp;quot; - Trial Development Group</gtr:description><gtr:id>4C3AA433-9166-4B67-B7F7-4CC60D61A3B0</gtr:id><gtr:impact>Clinical trial opens in May-2016. Results due in 10 years</gtr:impact><gtr:outcomeId>56d84c914c5d56.49074150-1</gtr:outcomeId><gtr:partnerContribution>Manchester, Warwick, St Gallen - clinical
London - statistical, operational, trials</gtr:partnerContribution><gtr:piContribution>Core group developing the &amp;quot;metformin comparison&amp;quot; in STAMPEDE which led to a clinical trial in prostate cancer with funding support from CRUK</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STRATOSPHERE Consortium (previousy S-STAMPEDE working group)</gtr:description><gtr:id>60B3D768-322B-4BEA-A8EB-D25525B357C8</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d84f24de4eb1.76889181-4</gtr:outcomeId><gtr:partnerContribution>Intellectual input into design
+ Sample processing by Almac</gtr:partnerContribution><gtr:piContribution>Developing a stratified medicine trial in prostate cancer - work ongoing but agreement that Almac will pay to process samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STRATOSPHERE Consortium (previousy S-STAMPEDE working group)</gtr:description><gtr:id>CE7447B4-9C14-4505-8062-D8919631D9AE</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d84f24de4eb1.76889181-2</gtr:outcomeId><gtr:partnerContribution>Intellectual input into design
+ Sample processing by Almac</gtr:partnerContribution><gtr:piContribution>Developing a stratified medicine trial in prostate cancer - work ongoing but agreement that Almac will pay to process samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE biobank</gtr:description><gtr:id>BBC1C478-A169-4C83-9DDC-57A133017304</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d850b3b41d70.44308347-1</gtr:outcomeId><gtr:partnerContribution>Will host samples.</gtr:partnerContribution><gtr:piContribution>Competitive process to choose sites to host a new Biobank for the STAMPEDE trial. Manchester and Cardiff were the winners. Grant funding has been submitted for.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swiss Group for Cancer Clinical Research (SAKK)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>B0F0D63D-BA87-40A5-803D-BD3ABB9AFDFA</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-4</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Almac Group</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Almac Sciences</gtr:department><gtr:description>STRATOSPHERE Consortium (previousy S-STAMPEDE working group)</gtr:description><gtr:id>A8923AED-2C07-42A4-ABFC-9FEB67BEE634</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d84f24de4eb1.76889181-5</gtr:outcomeId><gtr:partnerContribution>Intellectual input into design
+ Sample processing by Almac</gtr:partnerContribution><gtr:piContribution>Developing a stratified medicine trial in prostate cancer - work ongoing but agreement that Almac will pay to process samples</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Aventis</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>55E99B69-0E5F-4AE5-B751-E41DC443A942</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-1</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Section of Medicine ICR</gtr:department><gtr:description>STAMPEDE FTA elute card study</gtr:description><gtr:id>071AB7A1-AC91-4B85-B1FC-530829150608</gtr:id><gtr:impact>A report is in progress. A paper will follow. The research fellow doing the majority the work will include this in his PhD thesis.</gtr:impact><gtr:outcomeId>56d8803bc9d818.37903001-1</gtr:outcomeId><gtr:partnerContribution>ICR received and processed the samples. The quality of the samples on the cards was poorer than hoped. ICR used their own grant funding to try many ways to extract the best quality DNA data from the cards.</gtr:partnerContribution><gtr:piContribution>We had collected and stored blood samples as part of the STAMPEDE trial using FTA elute cards for simple collection, transport and storage. We entered a partnership with ICR to process the samples.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>AAF9B86B-C298-4A90-AE05-791632A288F6</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-5</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STRATOSPHERE Consortium (previousy S-STAMPEDE working group)</gtr:description><gtr:id>DF8281B7-9061-41AE-8FA1-AF096998D158</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d84f24de4eb1.76889181-3</gtr:outcomeId><gtr:partnerContribution>Intellectual input into design
+ Sample processing by Almac</gtr:partnerContribution><gtr:piContribution>Developing a stratified medicine trial in prostate cancer - work ongoing but agreement that Almac will pay to process samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clovis Oncology, inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>STAMPEDE docetaxel sample processing</gtr:description><gtr:id>AA31DFEA-FA10-459E-8B74-E7EF2DE401A9</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d85034983080.36587242-1</gtr:outcomeId><gtr:partnerContribution>Will receive, process and return samples</gtr:partnerContribution><gtr:piContribution>Agreement to process biopsy samples from STAMPEDE trial patients for DNA damage repair deficits</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Janssen-Cilag</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>1BD23459-1FCF-4CA8-9FAD-3E9565F5B801</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-8</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>hELP trial</gtr:description><gtr:id>5CCCA6D4-A414-4EA4-B5E9-216AC47F7469</gtr:id><gtr:impact>DOI 10.1186/s13063-015-1133-z</gtr:impact><gtr:outcomeId>56d85cc3218b37.16959017-1</gtr:outcomeId><gtr:partnerContribution>Leading clinical and operational and design aspects of trial.</gtr:partnerContribution><gtr:piContribution>Participated in the design of the hELP clinical trial which is led by Nottingham now that it is running. Gained funding through NIHR. We applied the MAMS design to design stage.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Briefing paper on docetaxel</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2484F139-CF98-4333-8F64-CE1690528B21</gtr:id><gtr:impact>We developed a briefing paper summarising the results and policy implications from STAMPEDE and STOPCaP. This was distributed via email and on the MRC CTU website to clinicians.</gtr:impact><gtr:outcomeId>56d85ceba17f87.77954323</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/13706/13710/docetaxel_prostate_cancer</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media coverage of STAMPEDE results</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2A46B1FC-03C5-42F5-B8FD-1C27064D9993</gtr:id><gtr:impact>The STAMPEDE results were covered in a press briefing in advance of the ASCO conference. They were then picked up by the BBC, Daily Telegraph, Daily Mail and others.</gtr:impact><gtr:outcomeId>56d861b70d1213.87821238</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.telegraph.co.uk/news/health/news/11603907/New-hopes-for-prostate-cancer-sufferers.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Film about the STAMPEDE docetaxel and zoledronic acid results for patients</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D1CF3227-6156-40DE-B78B-B8A6F40DD466</gtr:id><gtr:impact>This film explores the results of the STAMPEDE trial. STAMPEDE looked at whether adding docetaxel or zoledronic acid, or a combination of both, to standard treatment improves life expectancy for men with prostate cancer. It will be used at a series of Roadshows around the country, as well as being available online.</gtr:impact><gtr:outcomeId>56d86042c5c4d4.30272190</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://vimeo.com/149626704</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Film about the STAMPEDE docetaxel and zoledronic acid results for healthworkers</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1FC4109A-63F5-40C8-AD57-B56A1AA4E3E7</gtr:id><gtr:impact>This film explores the STAMPEDE results on whether adding docetaxel or zoledronic acid, or a combination of both, to standard treatment improves overall survival for men with prostate cancer. The film also includes an update on the active arms in STAMPEDE and future plans. It is aimed at healthworkers.</gtr:impact><gtr:outcomeId>56d860c28b7a69.19251465</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://vimeo.com/149631719</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Briefing paper on upfront zoledronic acid for prostate cancer</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F533639-23CB-45EE-8A94-0379A5B5EF15</gtr:id><gtr:impact>This briefing paper summarised the evidence on the upfront use of zoledronic acid for men with prostate cancer, based on the results of STAMPEDE and STOPCaP.</gtr:impact><gtr:outcomeId>56d85f386f3131.50693952</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/13706/13710/zoledronic_acid_prostate_cancer</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Impact of radiotherapy on node-positive prostate cancer: data from the control arm of STAMPEDE</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C6C275FC-4E1C-4440-A788-223395210E0F</gtr:id><gtr:impact>More than 1000 relevant people viewed the presentations. Discussions were stimulated. A paper is in development.

None yet (Nov-2014)</gtr:impact><gtr:outcomeId>5458ee07e45a61.74755739</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://annonc.oxfordjournals.org/content/25/suppl_4/iv255.2.abstract</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>188063</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Advisory and Awards Commitee (Cancer Research UK) -- enza+abi translational project (STAMPEDE)</gtr:description><gtr:end>2021-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>91CC2F6D-2483-4A96-B02D-1147272C1303</gtr:id><gtr:outcomeId>56d57205adb091.37490315</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1608605</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Advisory and Awards Commitee (Cancer Research UK) -- metformin comparison -- STAMPEDE</gtr:description><gtr:end>2026-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>88533523-9DA4-4BC2-A64D-94E7E558BC11</gtr:id><gtr:outcomeId>56d571cb7e3fb3.63814700</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EAU Guidelines on Prostate Cancer - PR07 (2015 clinical paper)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>European Association of Urology Guidelines on Prostate Cancer 2015</gtr:guidelineTitle><gtr:id>99CA15EA-7B0B-4B9C-8EA3-134CC62C29F5</gtr:id><gtr:impact>Quotation
6.3.3.3.6.4.1 MRC PR3/PR07 study - The National Cancer Institute of Canada (NCIC)/UK Medical Research Council (MRC)/Southwest Oncology Group (SWOG) intergroup PR3/PR07 study This study comprised 1,205 patients, consisting of T3-4 (n = 1057), or T2, PSA &amp;gt; 40 ng/mL (n = 119), or T2, PSA &amp;gt; 20 ng/mL and Gleason score &amp;gt; 8 (n = 25) and T-category unknown (n = 4), who were randomly assigned to lifelong ADT (bilateral orchidectomy or LHRH agonist), with or without radiotherapy (65-70 Gy to the prostate, with or without 45 Gy to the pelvic lymph nodes). After a median follow-up period of 6 years, the addition of radiotherapy to ADT reduced the risk of death from any cause by 23% (p = 0.03) and the risk of death due to PCa by 46% (p = 0.0001) [442, 443].</gtr:impact><gtr:outcomeId>56ddd1d4e05ab9.48421344</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Prostate CT SR (PMID: 26718929) NHS England guideline 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>NHS England: Clinical Commissioning Policy Statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone na&amp;iuml;ve metastatic prostate cancer (Reference: [B15/PS/a])</gtr:guidelineTitle><gtr:id>4E54B2A6-D468-4AF2-8405-018D935C9E00</gtr:id><gtr:impact>&amp;quot;NHS England has reviewed the evidence and concluded that it is sufficient to enable docetaxel to be routinely funded for the treatment of newly-diagnosed hormone na&amp;iuml;ve metastatic prostate cancer, where treatment with docetaxel is started within 12 weeks of commencing treatment with ADT.&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 26718929)</gtr:impact><gtr:outcomeId>56d04245c00bf3.59341868</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology - PR07 (paper 1)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2016 Prostate Cancer</gtr:guidelineTitle><gtr:id>74757666-F3A0-4237-96F2-66D7B0B223D8</gtr:id><gtr:impact>Quotation:
EBRT for Patients with High-Risk or Very High-Risk Disease EBRT has demonstrated efficacy in patients at high risk and very high risk. One study randomized 415 patients to EBRT alone or EBRT plus 3-year ADT. 180 In another study (RTOG 8531), 977 patients with T3 disease treated with EBRT were randomized to adjuvant ADT or ADT at relapse. 181 Two other randomized phase III trials evaluated long-term ADT with or without radiation in a population of patients who mostly had T3 disease. 182-184 In all four studies, the combination group showed improved disease-specific and overall survival compared to single- modality treatment.</gtr:impact><gtr:outcomeId>56ddcd89444774.84710200</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EAU Guidelines on Prostate Cancer - PR07 (2011 clinical paper)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>European Association of Urology Guidelines on Prostate Cancer 2015</gtr:guidelineTitle><gtr:id>5FC7B897-368F-48A8-80F5-C662E32275A1</gtr:id><gtr:impact>Listed in Table 6.3.3 with this citation. In text, updated results are used with an updated paper</gtr:impact><gtr:outcomeId>56ddd27d821560.03387734</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>STAMPEDE protocol</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>810BA764-A2E3-45FA-8712-7AD38A6E0A8D</gtr:id><gtr:impact>Results of PR07 in Nov-2011 led to a change in the control arm of the STAMPEDE trial for a substantive subset of patients. Led to the development of a further randomised question in STAMPEDE which drew in additional funding.</gtr:impact><gtr:outcomeId>pdkvhv9JnBQ</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EAU Guidelines on Prostate Cancer - PR05</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>European Association of Urology Guidelines on Prostate Cancer 2015</gtr:guidelineTitle><gtr:id>F098AF19-9453-4D3D-AEDC-CB67BBDF58A8</gtr:id><gtr:outcomeId>56ddd6bdb7be01.19176381</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EAU Guidelines on Prostate Cancer - RT01 (2014 clinical paper)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>European Association of Urology Guidelines on Prostate Cancer 2015</gtr:guidelineTitle><gtr:id>528884DE-5F37-4B46-A300-934978A0468A</gtr:id><gtr:impact>Table 6.3.6 and text:
6.3.3 Radiotherapy for localised PCa
6.3.3.1 Dose escalation
Several randomised studies (see below) have shown that dose escalation (range 74-80 Gy) has a significant
impact on 5-year survival without biochemical relapse [391-397]. These trials have generally included patients
from several risk groups, and the use of neoadjuvant/adjuvant hormone therapy (see below) has varied.
To date, no trials have shown that dose escalation results in an OS benefit. However, the trials have been
remarkably consistent in reporting improvements in freedom from biochemical progression in patients treated
with dose-escalated radiotherapy.
In everyday practice, a minimum dose of &amp;gt; 74 Gy is recommended for EBRT + hormone therapy.
Currently, it is not possible to make different recommendations according to the patient's risk group.</gtr:impact><gtr:outcomeId>56ddd41b4de731.63374331</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EAU Guidelines on Prostate Cancer - PR07 (2015 QL paper)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>European Association of Urology Guidelines on Prostate Cancer 2015</gtr:guidelineTitle><gtr:id>0169D303-6BB9-4600-828A-800A956FE855</gtr:id><gtr:impact>Quotation
6.3.3.3.6.4.1 MRC PR3/PR07 study - The National Cancer Institute of Canada (NCIC)/UK Medical Research Council (MRC)/Southwest Oncology Group (SWOG) intergroup PR3/PR07 study This study comprised 1,205 patients, consisting of T3-4 (n = 1057), or T2, PSA &amp;gt; 40 ng/mL (n = 119), or T2, PSA &amp;gt; 20 ng/mL and Gleason score &amp;gt; 8 (n = 25) and T-category unknown (n = 4), who were randomly assigned to lifelong ADT (bilateral orchidectomy or LHRH agonist), with or without radiotherapy (65-70 Gy to the prostate, with or without 45 Gy to the pelvic lymph nodes). After a median follow-up period of 6 years, the addition of radiotherapy to ADT reduced the risk of death from any cause by 23% (p = 0.03) and the risk of death due to PCa by 46% (p = 0.0001) [442, 443].</gtr:impact><gtr:outcomeId>56ddd387b13874.03573640</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology - PR07 (paper 2)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2016 Prostate Cancer</gtr:guidelineTitle><gtr:id>6F042C3F-A86A-44E9-BF27-0CB1C9BC3D06</gtr:id><gtr:impact>Quotation:
EBRT for Patients with High-Risk or Very High-Risk Disease EBRT has demonstrated efficacy in patients at high risk and very high risk. One study randomized 415 patients to EBRT alone or EBRT plus 3-year ADT. 180 In another study (RTOG 8531), 977 patients with T3 disease treated with EBRT were randomized to adjuvant ADT or ADT at relapse. 181 Two other randomized phase III trials evaluated long-term ADT with or without radiation in a population of patients who mostly had T3 disease. 182-184 In all four studies, the combination group showed improved disease-specific and overall survival compared to single- modality treatment.</gtr:impact><gtr:outcomeId>56ddce59cb3415.01164692</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology - RT01</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2016 Prostate Cancer</gtr:guidelineTitle><gtr:id>6E98332C-9162-472E-A8B1-06F2CD8A8AE4</gtr:id><gtr:impact>Quotation:
These techniques have permitted safer dose escalation, and resu lts of randomized trials have suggested that dose escalation is associated with improved biochemical outcomes. 163-168 Kuban and colleagues 166 published an analysis of their dose-escalation trial of 301 patients with stage T1b to T3 prostate cancer. Freedom from biochemical or clinical failure was higher in the group randomized to 78 Gy compared to 70 Gy (78% vs. 59%, P = .004) at a median follow-up of 8.7 years. The difference was even greater among patients with diagnostic PSA &amp;gt;10 ng/mL (78% vs. 39%, P = .001). An analysis of the National Cancer Data Base found that dose escalation (75.6-90 Gy) resulted in a dose- dependent improvement in overall survival for men with intermediate- or high-risk prostate cancer. 169 In light of these findings, the conventional 70 Gy dose is no longer considered adequate. A dose of 75.6 to 79.2 Gy in conventional fractions to the prostate (with or without seminal vesicles) is appropriate for patients with low-risk cancers. Intermediate-risk and high-risk patients should receive doses up to 81.0 Gy. 159,170,17</gtr:impact><gtr:outcomeId>56ddcf740767d2.18975035</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ESMO Guidelines on Prostate Cancer 2015 - PR07</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2015</gtr:guidelineTitle><gtr:id>5CE1CA62-86B7-42F1-8F9A-7FA0AC1D5DEE</gtr:id><gtr:impact>Quotation
The case for adding radical local treatment for men with high-risk localised and locally advanced disease is based on two randomised, controlled trials. The Scandinavian Prostate Cancer Group Study 7 (SPCG-7) trial included 875 men who received 3 months of combined androgen blockade followed by flutamide monotherapy. They were randomised by whether or not they were to receive radical radiotherapy (RT) to the prostate [14]. It showed a beneficial impact of radical RT in terms of cause-specific (11.9% versus 23.9%, P &amp;lt; 0.001) and overall mortality (29.6% versus 39.4%, P = 0.004). The NCIC/MRC trial randomised high-risk patients to either lifelong androgen deprivation therapy (ADT) alone or to ADT plus RT. The addition of RT improved the 7-year survival probability from 66% to 74% (P = 0.003) [15]. 
Recommendations ? 
Primary ADT alone is not recommended as standard initial treatment of non-metastatic disease [III, B]. ? Options for patients with high-risk or locally advanced prostate cancer include external beam RT plus hormone treatment [I, B] or RP plus pelvic lymphadenectomy [III, B].</gtr:impact><gtr:outcomeId>56ddd97e26aee0.37495591</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/26205393</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>STAMPEDE trial protocol version 14</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>C641E5E1-16FB-4742-A954-6C51BBB30BB8</gtr:id><gtr:impact>Implemented a clinical trial that rolled out an improvement to the standard-of-care</gtr:impact><gtr:outcomeId>56d85eeb6cfec8.62940281</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EAU Guidelines on Prostate Cancer - RT01 (2007 toxicity paper)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>European Association of Urology Guidelines on Prostate Cancer 2015</gtr:guidelineTitle><gtr:id>088C48ED-FDFF-4E8D-83FA-5500B1FF6D02</gtr:id><gtr:impact>Cited in guidelines</gtr:impact><gtr:outcomeId>56ddd55661bc91.39879913</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Prostate CT SR (PMID: 26718929) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.2.2016 Prostate Cancer</gtr:guidelineTitle><gtr:id>5CCE32A5-40E5-4CCB-B9C1-A1C22FA99CB4</gtr:id><gtr:impact>&amp;quot;Meta-analyses of randomized controlled trials also concluded that docetaxel provides a significant OS benefit in this setting, with no evidence that the benefit was dependent on the volume of disease&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 26718929)</gtr:impact><gtr:outcomeId>56d041b9d6de21.16742040</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology - RT01</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>US National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2016 Prostate Cancer</gtr:guidelineTitle><gtr:id>9E7AF83E-CECD-48E3-8B84-87B9F780F2DA</gtr:id><gtr:impact>Quotation:
EBRT for Patients with High-Risk or Very High-Risk Disease EBRT has demonstrated efficacy in patients at high risk and very high risk. One study randomized 415 patients to EBRT alone or EBRT plus 3-year ADT. 180 In another study (RTOG 8531), 977 patients with T3 disease treated with EBRT were randomized to adjuvant ADT or ADT at relapse. 181 Two other randomized phase III trials evaluated long-term ADT with or without radiation in a population of patients who mostly had T3 disease. 182-184 In all four studies, the combination group showed improved disease-specific and overall survival compared to single-modality treatment.</gtr:impact><gtr:outcomeId>56ddcc66eda007.25548880</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>584E318E-7411-4E88-898A-1D4D9D264C3B</gtr:id><gtr:title>Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af0707d338e2c1c3c05688ae01f64aed"><gtr:id>af0707d338e2c1c3c05688ae01f64aed</gtr:id><gtr:otherNames>Ahmed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b69d8d9b0137.33010439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6373C210-6C8D-4D43-8263-F901B627B1B5</gtr:id><gtr:title>Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc1cebf8d7bdc29258b3035f4f93eba7"><gtr:id>cc1cebf8d7bdc29258b3035f4f93eba7</gtr:id><gtr:otherNames>Andreassen CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>58b69d8dd6d0a5.41306724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>684B1C07-D124-420F-AC26-BDF639DB79B1</gtr:id><gtr:title>Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d2ac172ff6bc9256060246dd201744c"><gtr:id>4d2ac172ff6bc9256060246dd201744c</gtr:id><gtr:otherNames>Lemanska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5a995f23d27673.78772051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0965415-287C-4B42-AC7D-7218AEE2C096</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58b98f57a1f775.39638054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24B97C8B-FF25-4B9A-BD71-FECB7412A396</gtr:id><gtr:title>Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a2b4a60143f694fb37017f02d8dd28a"><gtr:id>9a2b4a60143f694fb37017f02d8dd28a</gtr:id><gtr:otherNames>Kerns SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>596bcfcb3b2241.29523464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCFE1BF9-F90E-4DD1-985E-4D19DE449C72</gtr:id><gtr:title>A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5457bf54b05f38.90787561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8BD443D-35E6-493E-B8BB-288C123CD02A</gtr:id><gtr:title>Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397).</gtr:title><gtr:parentPublicationTitle>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d2ac172ff6bc9256060246dd201744c"><gtr:id>4d2ac172ff6bc9256060246dd201744c</gtr:id><gtr:otherNames>Lemanska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-9343</gtr:issn><gtr:outcomeId>58dd0da8d613f8.46660300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE9CF8DA-DB1B-4AA9-A991-75664F68F6DC</gtr:id><gtr:title>Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.</gtr:title><gtr:parentPublicationTitle>JAMA oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2374-2437</gtr:issn><gtr:outcomeId>56d5737f730bd2.67465791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E6775A-C586-4E23-A190-3850A162A290</gtr:id><gtr:title>Survival with Newly Diagnosed Metastatic Prostate Cancer in the &amp;quot;Docetaxel Era&amp;quot;: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5457bf54394366.75428053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BD9435B-0D88-44BE-A9E4-5F1FFEE40647</gtr:id><gtr:title>Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89617b9d24b04255c06955063acd4a7c"><gtr:id>89617b9d24b04255c06955063acd4a7c</gtr:id><gtr:otherNames>Mason MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56d5737f99c8f6.82782342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2440A10-F6A8-4448-BE79-7B0BB5AA9576</gtr:id><gtr:title>Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>56d57380cfa115.89781933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8BEA056-C9FB-4194-BCB7-9236A8005803</gtr:id><gtr:title>Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology focus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7744e8e09b3d0fd0cf776341fadf5194"><gtr:id>7744e8e09b3d0fd0cf776341fadf5194</gtr:id><gtr:otherNames>South A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2405-4569</gtr:issn><gtr:outcomeId>56d5737fc97886.40936996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69ADA7CA-0260-486D-998A-3AF2942ABE3C</gtr:id><gtr:title>Adding Celecoxib With or Without Zoledronic Acid for Hormone-Na&amp;iuml;ve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89617b9d24b04255c06955063acd4a7c"><gtr:id>89617b9d24b04255c06955063acd4a7c</gtr:id><gtr:otherNames>Mason MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>58dd0e1ace8d79.35774411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55EE4573-31B6-4A18-9CF4-CB152B64AA04</gtr:id><gtr:title>A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc4389ae07293d859ae1a38ce4928c24"><gtr:id>fc4389ae07293d859ae1a38ce4928c24</gtr:id><gtr:otherNames>Fachal L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5457bf545e2736.26970986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8B3F485-44C2-4124-AA3A-D8D5D8A72234</gtr:id><gtr:title>Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>5457bf5483e831.04764696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A961D090-28B3-4F17-92C8-E235A24C98AA</gtr:id><gtr:title>Postoperative radiotherapy after radical prostatectomy: let's work together to tackle the known unknowns.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b8c0f9f2a167a9c3c7bdc612ef4685c"><gtr:id>1b8c0f9f2a167a9c3c7bdc612ef4685c</gtr:id><gtr:otherNames>Parker CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5457bf54112fd4.60555296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2A4E986-B678-4D0A-A45C-D69A500A6A91</gtr:id><gtr:title>Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c046ae6f178734e3c27748ade971b75c"><gtr:id>c046ae6f178734e3c27748ade971b75c</gtr:id><gtr:otherNames>Brundage M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56d5737e822f38.21533292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88B1B464-2793-43F3-8860-6C1D66720F0A</gtr:id><gtr:title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d98c29beb6dc28d0f861418f49d65494"><gtr:id>d98c29beb6dc28d0f861418f49d65494</gtr:id><gtr:otherNames>Ahmed H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b98c09ba4404.16448606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75F7AA70-C01B-4652-9E35-BF25B8876D45</gtr:id><gtr:title>Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d53b218500ae8d4b2ed732abfeb2ee1"><gtr:id>7d53b218500ae8d4b2ed732abfeb2ee1</gtr:id><gtr:otherNames>Faria R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5a9a999e524e11.79609928</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/6</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>